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Parallel analysis of tri-molecular biosynthesis with
cell identity and function in single cells
Samuel C. Kimmey 1,2, Luciene Borges 2, Reema Baskar 2,3 & Sean C. Bendall 2
Cellular products derived from the activity of DNA, RNA, and protein synthesis collectively
control cell identity and function. Yet there is little information on how these three bio-
synthesis activities are coordinated during transient and sparse cellular processes, such as
activation and differentiation. Here, we describe Simultaneous Overview of tri-Molecule
Biosynthesis (SOM3B), a molecular labeling and simultaneous detection strategy to quantify
DNA, RNA, and protein synthesis in individual cells. Comprehensive interrogation of bio-
synthesis activities during transient cell states, such as progression through cell cycle or
cellular differentiation, is achieved by partnering SOM3B with parallel quantification of select
biomolecules with conjugated antibody reagents. Here, we investigate differential de novo
DNA, RNA, and protein synthesis dynamics in transformed human cell lines, primary acti-
vated human immune cells, and across the healthy human hematopoietic continuum, all at a
single-cell resolution.
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The integrated output of DNA replication, RNA transcrip-tion, and protein synthesis imparts gene expression andfunction in an individual cell. Importantly, the activity of
these processes is tightly regulated to maintain tissue homeostasis,
or modulated to facilitate changes in cell-state, such as progres-
sing through the cell cycle1 or differentiation2. Much of our
collective knowledge of DNA3, RNA4–6, and protein7,8 synthesis
in complex systems is derived from labeling cells or tissue of
interest with metabolic precursor molecules for a set period of
time, followed by fixation and analysis. Conventional approaches
to measure these processes use radio-labeled precursor
molecules6,7,9, with newer methods moving toward click-5,10 or
immuno-chemistry4,6,7 based detection to measure specific
synthesis activity in individual cells.
Recent investigations to better understand the regulation of
biosynthesis processes in heterogeneous cell populations highlight
the strength of layering single-cell activity measurements with
parallel quantification of target biomolecules on high-throughput
machines7,8,10–12. These investigations unified biomarkers
informing single cell phenotype and function with their protein
synthesis activity7,10,12, or even proliferative history8,11, as mea-
sured by conventional flow cytometry. In one recent example,
investigators characterized the activity of protein synthesis in
developmentally isolated hematopoietic populations from mouse
bone marrow, establishing a regulated control of protein synthesis
activity during hematopoietic cell specification10,12. While these
studies demonstrate the benefit of measuring protein synthesis
activity on single-cell platforms, methodology and reagents to
provide parallel assessment of de novo RNA synthesis have yet to
be presented. However, their development would provide a
unique and novel single-cell dataset unifying cellular biosynthesis
activity with cell phenotype and function. Finally, while these
recent studies focused on protein synthesis activities in complex
cell systems of cell lines and primary mouse tissue7,8,10–12, there
are few reports on comparable human tissue9,13, those of which
utilized radioactive precursors and only reported activity in broad
bone marrow morphological groups.
One technical reason inhibiting such studies is the lack of
integrated methods that enable fast labeling and robust quanti-
fication of de novo molecules of DNA, RNA, and protein, in
parallel with simultaneous recording of select biomolecules. The
integration of such measurements would allow investigators to
probe multiple biosynthesis processes in diverse cell populations
with many discrete cell-types or -states by generating multifaceted
single-cell datasets, which can be rigorously analyzed in silico.
The development of mass-cytometry enabled simultaneous
detection of up to 45 distinct biomolecules at a rate up to 1000
cells per second with individually labeled antibody reagents, and
importantly does not suffer from technical artifacts of auto-
fluorescence or spectral overlap currently present in fluorescent
flow cytometry14–16. However, one important technical limitation
to consider when analyzing cells with mass-cytometry is the
inability to sort cells on measured characteristics, as the mea-
surement process is destructive. However, even with its destruc-
tive nature, mass-cytometry enables routine measurements of
diverse repertoires of biomolecules, yielding thousands to mil-
lions of multiplexed single-cell data from a single experiment.
The combination of accessible parameter space and sample
throughput enable the necessary complexity and depth to capture
low-abundant cell types present at frequencies as low as 1 in
10,00016. Additionally, the ability to integrate sample-barcoding
seamlessly into cell staining steps enables simultaneous staining
and analysis of as many as 20 experimental conditions17, pro-
viding robust quantitative comparison and eliminating technical
staining variability between individual samples. Thus, we believed
this platform would enable robust and parallel assessment of
biosynthesis activities and cell biology across diverse cell popu-
lations and experimental conditions.
Drawing on recently developed methods to quantify disparate
biosynthesis activities and leveraging multiplexed single cell
measurement technologies, we developed a simple non-genetic,
tri-molecular pulse-labeling strategy to simultaneously quantify
the DNA, RNA, and protein synthesis activity of individual cells
in a high-throughput manner. A method we termed, Simulta-
neous Overview of tri-Molecule Biosynthesis, or SOM3B. Here,
we use SOM3B to provide a detailed overview of DNA, RNA, and
protein synthesis in asynchronously dividing cell lines, primary
samples of healthy human whole blood, and bone marrow. For
each context, we highlight the activity of these processes in
individual cells across the cell-cycle, during small-molecule
induced cell activation, and across developmentally organized
cell phenotypes, respectively.
Results
Labeling and detection of nascent DNA, RNA, and protein. To
label nascent biomolecules of DNA, RNA, and protein, we pulsed
live cells with an optimized mixture of 5-Iodo-2′-deoxyuridine
(IdU), 5-Bromouridine (BRU), and puromycin. Importantly,
these three molecules were selected due to their previously
established utility in cell activity assays in order to quantify cel-
lular biosynthesis across diverse biological systems (IdU3,18,19;
BRU4,6,20–25; puromycin7,8,10,11,26,27). The numerous demon-
strated applications of these metabolic pre-cursor molecules on
their own, in partnership with multiplex-capable detection sys-
tems, such as flow cytometry or immunofluorescence imaging,
encouraged us to unify all three in combination in order to
provide a snapshot of biosynthesis activities in cell-systems of
choice. Further, the potential to obtain detailed information by
unifying such metabolic incorporation information with simul-
taneous biomarkers abundance using multiplexed detection
technologies3,6,7,11,18,19,28, led us to quantify the activity of de
novo DNA, RNA, and protein synthesis on a platform, which
enablable a high level of combinatorial measurements (i.e. mass-
cytometry).
In SOM3B, each metabolic analogue can enter live cells and is
incorporated into actively synthesized macro molecules of DNA,
RNA, and protein, respectively (Fig. 1a). After as little as 30 min,
the labeling mixture is removed and cells are fixed and stained
immediately with metal-isotope labeled antibodies, or fixed and
cryopreserved for later sample preparation and analysis. Incor-
poration of each molecule was quantified on a cell-by-cell basis by
mass-cytometery, detecting either elemental iodine for IdU3 or
lanthanide tagged monoclonal antibodies for BRU6 and pur-
omycin7 (Fig. 1b–e; Supplementary Fig. 1, see methods).
Along with the concentration of IdU needed to quantify DNA
synthesis by mass-cytometry3, we identified optimal conditions
for, and concentrations of, BRU and puromycin to label live cells.
HeLa cells treated with increasing concentrations of BRU
(Fig. 1b), or puromycin (Fig. 1c), were stained with lanthanide
labeled monoclonal antibodies against BRU and puromycin,
respectively (detection optimization, Supplementary Fig. 1a).
Importantly, selection of optimal concentration of metabolic pre-
cursor, and antibody reagents to detect the respective incorpo-
rated molecule, is made possible by performing titrations of both
classes of reagent on unlabeled and labeled cells. Concentrations
of BRU and puromycin were chosen based on observed signal-to-
noise ratio in order to provide a large dynamic range of detectable
synthesis activities. Concentrations of metal-isotope conjugated
antibody used for subsequent SOM3B experiments were selected
by comparing the observed background signal in un-labeled cells
with the incorporated molecules in labeled cells (Supplementary
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Fig. 1a and Supplementary Table 1). Concentrations of BRU and
puromycin were selected based on a combination of previously
reported uses of these molecules for labeling purposes7,11,25, and
observation of incorporation compared with unlabeled controls
stained with matching concentration of labeled antibody (Fig. 1b,
c). Importantly, concentrations of pre-cursor molecule and
antibody reagents for new cell types should be optimized and
selected to minimize background antibody staining in un-labeled
conditions (Fig. 1b, c, red histogram trace).
Notably, inclusion of one or more RNase inhibitors during
antibody staining failed to increase overall BRU signal, indicating
labeled RNA remains stable and detectable with conventional
mass-cytometry staining methods. Interestingly, when compared
to sample staining conditions including RNase inhibitors, there is
improved detection of incorporated BRU when staining is
performed without (Supplementary Fig. 1b). This is likely
explained by increased exposure of BRU antigen due to the
activity of RNase enzymes. Enzyme-improved detection of
incorporated nucleotides is routinely performed when nascent
DNA is labeled with BRdU, in which fixed cells are pre-treated
with low concentrations of DNase I to expose antigen occluded by
compacted DNA or bound protein prior to antibody-detection of
BRdU29,30. Finally, simultaneous labeling and detection of cells
with IdU, BRU, and puromycin did not significantly interfere
with quantification or cell signaling activity when compared with
single- or double-molecule labeling controls (Supplementary
Fig. 1d–f). Altogether, we established SOM3B as a fast and robust
strategy to simultaneously capture complementary synthesis
activities at the single cell level.
We further assessed specificity and quantification of SOM3B
with HeLa cells pre-treated with increasing concentrations of
Actinomycin D (ActD) or Cycloheximide (CHX), which block
synthesis of RNA31 or protein, respectively32 (Fig. 1d, e). As
expected, HeLa cells pre-treated with ActD for only 30 min prior
to labeling displayed dose-dependent inhibition of the median
BRU incorporation, while the same treatment with CHX also led
to a decrease in median puromycin incorporation. While ActD
treatment resulted in little change of incorporated IdU or
puromycin (Supplementary Fig. 2a), HeLa cells pre-treated with
CHX displayed a dose-dependent decrease in median BRU and
IdU incorporation, yet maintain a similar proportion of cells
actively synthesizing DNA (Supplementary Fig. 2b). These results
highlight the dependence of DNA33 and RNA34 activity on
continued protein synthesis for this cell line, a process previously
described with the assistance of radioactive pre-cursor molecules
in bulk assays and confirmed here using our SOM3B single-cell
approach. Collectively, these results reinforce SOM3B as a
simplified approach to capture specific biosynthetic activities by
observing predictable changes over large measurement dynamic
ranges in individual cells.
Single-cell biosynthesis dynamics across the cell-cycle. Insights
into cell cycle regulation are compounded by asynchronous bio-
synthesis activities and cell states, involving numerous regulators.
For instance, dividing eukaryotic cells suppress nascent tran-
scription (i.e. RNA synthesis)1,35 and protein synthesis (up to
35%)36 during mitosis, relieving suppression after re-entry into
interphase36. However, our understanding of the activity of RNA
and protein synthesis during cell-cycle progression is derived
from assays typically involving chemical synchronization and
large input material35,36. Importantly, this obfuscates the reg-
ulatory timing of biosynthesis activity as cells progress through
the least frequent (1–2%, Fig. 2a), and shortest phase of the cell
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Fig. 1 SOM3B, simultaneously captures de novo DNA, RNA, and protein synthesis in transient, asynchronous cell systems. a Overview of biomolecule
labeling with 5-Iodo-2-deoxyuridine (IdU), 5-Bromourdine (BRU), and puromycin incorporation into each biomolecule based on their active synthesis.
b, c Mass-cytometry quantification of incorporated BRU (b) and puromycin (c) in HeLa cells pulsed with increasing concentration of each label molecule,
detected with isotope labeled antibodies. d, e Histogram of BRU and puromycin incorporation in HeLa cells pre-treated with increasing concentration of
Actinomycin D (ActD) (d) or Cycloheximide (CHX) (e), respectively. Experiments were performed multiple times, and representative plots shown
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cycle, as mitosis lasts only 1 h in HeLa cells37. Thus, with this
system of a relatively small fraction of total cells occupying a
transient cell-state (i.e. mitosis) with previously appreciated dis-
crete biosynthesis activities, we sought to test the sensitivity of
SOM3B and quantify dynamic biosynthesis characteristics across
a single mixed populations of cell-states. Accordingly, we com-
bined SOM3B with several specific antibodies against cell-cycle
specific markers in order to capture and characterize synthesis
activity of asynchronously dividing HeLa and Jurkat cell lines3
(Supplementary Table 1).
As expected and in agreement with recent image-based
analysis35, we observed a marked decrease in HeLa cell RNA
synthesis activity during the transition from the G2-phase into
mitosis. Mitotic initiation is indicated by increased abundance of
phosphorylated histone H3-Ser2838 (p-HH3 Fig. 2b, arrow).
Interestingly, while Jurkat cells also modestly suppressed RNA
synthesis activity in mitotic cells relative to G2-phase cells, the
degree of suppression is less than that observed for HeLa cells
(Fig. 2c). In contrast to RNA synthesis, protein synthesis
remained active in early mitotic cells and was down-regulated
only in cells at later stages of mitosis (reduced CyclinB1
expression; Fig. 2b, c, arrow head). One mechanism maintaining
translation in early mitotic cells is high activity of the mTOR
pathway39, which results in inhibitory hyper-phosphorylation of
endogenous translation initiation repressor, Eukaryotic transla-
tion initiation factor 4E-binding protein 1, abbreviated as 4EBP1.
Indeed, we observed the highest phosphorylation of 4EBP1
(p-4EBP1) in the same early mitotic cells (Fig. 2b, c, red boxes).
Altogether, these results establish the capability of combining
SOM3B with intracellular markers to capture and visualize
regulation of synthesis activity in rare, and transient cells states
found within mixed cell populations.
RNA and protein synthesis in primary peripheral immune
cells. Immune cell activation is a coordinated series of tran-
scription and translation events that can lead to cell division in a
context-dependent basis as a result of prolonged stimulation with
specific immune-modulatory molecules. Human peripheral blood
mononuclear cells (PBMCs) lay in a dormant state until a cell-
type specific immune stimulation modulates gene40 and protein8
expression, releasing specific soluble signaling factors to further
instruct the immune system. Recent investigations in mouse
highlight dynamic global protein synthesis rates in primary
lymphocyte subsets after 16–48 h of ex vivo cellular activation
with immune-stimulatory molecules11, highlighting both a mea-
sureable increase in active protein synthesis and post-
translational modifications of signaling molecules via phosphor-
ylation. Yet, how protein and RNA synthesis is immediately
modulated in individual immune cells over the course of short-
term cell activation before cell division, or the dynamics of these
synthesis activities during human immune-cell activation,
remains unexplored.
Thus, we employed SOM3B to directly compare the sequential
layers of ex vivo human PBMC activation when stimulated with
broad immune-activation molecules, phorbol 12-myristate 13-
acetate (PMA) and ionomycin41, in a time-course up to 5 h
(Fig. 3a). Importantly, we employed reagents, which enable
instant fixation of nucleated cells, and lyses of red blood cells, in
order to capture the time-dependent biosynthesis activity and
phosphorylation states as a result of stimulation (see methods). In
addition to the discrete layers of RNA and protein synthesis, 15+
phenotypic biomolecules were simultaneously measured in order
to assess the unique responses of major immune sub-populations
present in whole blood. Importantly, palladium-isotope sample
barcoding reagents17 were applied before pooling fixed cells from
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Fig. 2 de novo RNA and protein synthesis is suppressed in mitotic cells of asynchronously dividing human cell lines. a Cell-cycle phase breakdown of HeLa
and Jurkat cell lines labeled with SOM3B. b Biaxial plot depicting cell-cycle progression of asynchronously dividing HeLa cells overlaid with SOM3B
expression and phosphorylation status of 4EBP1-Thr37/46, arrow indicates early mitotic HeLa cells with low de novo RNA synthesis. (CyclinB1neg—G0/
G1, CyclinB1mid—S, CyclinB1high—G2, p-HH3-Ser28high—mitotic; expression color range—IdU: 0, 3460; BRU: 0, 697; Puromycin: 1.5, 600; p4EBP1: 0,
73). c Biaxial plot depicting cell-cycle progression of asynchronously dividing Jurkat cells overlaid with SOM3B expression and phosphorylation status of
4EBP1-Thr37/46. Arrow head in b and c mark downregulation of de novo protein synthesis in mitotic cells (CyclinB1neg—G0/G1, CyclinB1mid—S,
CyclinB1high—G2, p-HH3 (S28)—mitotic; expression color range—IdU: 0, 676; BRU: 2, 1030; Puromycin: 8.5, 1060; p4EBP1: 5, 114). Experiments were
performed multiple times, representative plots shown, 115,000+ cell events displayed for each cell line
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all time-points into a single tube, followed immediately by
antibody staining (Supplementary Table 2).
Focusing first on biosynthetic activities in unperturbed PBMCs,
we ensured SOM3B labeling was robust and did not interfere with
cellular fitness or viability (Fig. 3b, c). Importantly, control
samples from the same PBMC donor left unlabeled, or pre-
treated with specific inhibitors, indicated minimal effect on cell
fitness as there were little change in the proportion of cells with
activated pro-apoptotic caspase molecules or in cell viability,
examined by antibody staining and cisplatin exclusion42,
respectively (Fig. 3b). For remaining analysis of PBMC experi-
ments, single cell data was restricted to mono-nuclear cells in
silico after non-viable and non-mononuclear single-cell events
were removed, in addition to excluding granulocytes, red blood
cells, and platelets (Supplementary Fig. 3). Mono-nuclear single-
cell data from all samples clustered into phenotype-sub groups
with SPADE43 (SPADE column, Supplementary Table 2) illus-
trates the specificity of SOM3B when labeling whole blood ex vivo
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by predictably blocking SOM3B label incorporation with specific
inhibitors (Fig. 3c; cluster phenotype description, Supplementary
Table 3).
In SOM3B labeled PBMCs observed at baseline, we find B-cells
as the predominant immune cell subset with the highest median
RNA synthesis activity while maintaining protein synthesis
comparable to other lymphocyte sub-populations. However,
myeloid cells including monocytes and dendritic cells maintained
a higher median basal activity of protein synthesis facilitated by
high activity of the mTOR pathway, indicated by phosphorylation
of 4EBP1 (Fig. 4a). Parallel quantification of signal pathway
members’ post-translational modification (i.e. phosphorylation),
downstream modulation of biomolecule synthesis, and cytokine
production, enabled robust analysis of the immediate cellular
response to PMA/ionomycin (Fig. 4b; Supplementary Table 2).
As expected, PMA/ionomycin stimulated PBMCs, across all
identified subsets, immediately (i.e. 15 min) responded beginning
with increased ribosomal protein S6 and 4EBP1 phosphorylation,
while surface expression of the classical protein activation marker
CD69 emerged only with longer stimulation (Fig. 4b, 2 h).
Relative to time 0 h, upregulation of the median de novo RNA
synthesis activity occurred during the first hour of stimulation
before returning to baseline, followed by activation of de novo
protein synthesis and differential detection of cytokines (Fig. 4b,
2 h & 5 h). Interestingly, despite similar cytokine production
profiles (Fig. 4b, red box), T- and NK- lymphoid cell subsets had
very different protein synthesis kinetics where NK cells more
closely resembled the DC and monocyte myeloid cell lineages,
indicating global features of their immune response kinetics more
aligned with that of the innate immune system (Fig. 4b, purple
line). Collectively, these results demonstrated the ability to use
SOM3B to uncover timing of biomolecule synthesis activity in
coordination with other differential facets of the immune
response.
Dynamic biosynthesis across a human hematopoietic spec-
trum. Recent investigations uncovered regulated control of pro-
tein synthesis in adult stem cells of mice10,28 and drosophila44.
However, the dynamics of protein synthesis, RNA synthesis, and
cell proliferation (DNA synthesis) across human adult stem cells
and their progeny has yet to be extensively explored in part due to
inadequate methods and limitations in obtaining sufficient
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amounts of primary sample material. Leveraging our ability to
comprehensively phenotype the major developmental stages in
human hematopoiesis41, we sought to probe the biosynthesis
characteristics in healthy human bone marrow with SOM3B.
After we confirmed labeling primary human bone marrow with
SOM3B reagents did not interfere with cellular fitness (Supple-
mentary Fig. 4), we integrated SOM3B with approaches our lab
pioneered to deeply phenotype developmental progression in
human hematopoiesis41,45 in order to characterize the activity of
macromolecule synthesis during human bone marrow home-
ostasis in two healthy adult donors (Supplementary Table 4). We
first removed non-immune single-cell data in silico, yielding over
325 thousand single cell events for each donor (Supplementary
Fig. 5). When biosynthesis activity was visualized across all
immune cell data in bone marrow datasets, we observed cells
predominantly devoted to protein, or RNA synthesis (Fig. 5a,
Supplementary Fig. 6a, arrows), while cells actively synthesizing
DNA maintained a high activity of protein synthesis and variable
transcriptional activity in both donors (arrow head).
To assess the functional association of biomolecular synthesis
with cell identity, we organized single cell data by immune
biomarkers with SPADE41, identifying 33 major phenotypic
populations (Supplementary Table 5 and 6). We observed an
elevated median protein synthesis activity in progenitor cells
relative to Hematopoietic Stem Cells (HSCs) across human
marrows ex vivo, in agreement with reported results of in vivo
protein synthesis in mouse bone marrow10,12 (Fig. 5b, Supple-
mentary Fig. 6b). We also saw a dramatic increase in both RNA
and protein synthesis during progression into the highly
proliferative erythroid lineage (Fig. 5c, Supplementary Fig. 6c,
gray box). On the opposite end of the spectrum, plasma cells, the
memory B-cells tasked with maintenance of humoral immunity
(i.e. antibody production), were the most predominate population
with high protein synthesis and rRNA expression, yet little
detectable de novo RNA synthesis9 (Fig. 5b, c, Supplementary
Fig. 6b, c, arrow). Importantly, statistically evaluating the
similarity of multivariate distributions46,47 of RNA and protein
biosynthesis activity between the HSC population and each
identified population established significant modulation of these
activities during developmental periods of human hematopoiesis,
relative to a baseline activity in HSCs (Fig. 5c, Supplementary
Table 6). In brief, the similarity of RNA and protein synthesis is
measured using FlowMap-FR46, a recently developed method
based on the Freidman-Rafsky nonparametric test statistic47.
With this method, the distributions of BRU and puromycin
incorporation are together evaluated between the HSC population
and all other identified cell-subsets within each bone marrow
donor dataset. Importantly, control comparisons between two
populations sampled from the same phenotypic population
always returned the highest probability of similarity (Supple-
mentary Table 6, HSC vs HSC). These results highlight tightly
controlled biomolecular synthesis traits intrinsic to cell function
and identity across the human hematopoietic hierarchy uncov-
ered by SOM3B, and further highlight the utility of partnering
SOM3B with high-dimensional analysis tools to interrogate these
activities across complex systems.
Homeostasis of B-cells is maintained in the bone marrow by a
series of developmentally discrete B-cell identities with unique
cell activities, including periods of proliferation and reorganiza-
tion of signaling network profiles45. Leveraging our prior work in
establishing single cell developmental trajectories, we used
Wanderlust45 to organize emergent B cells in the marrow to
reveal coordination points of DNA, RNA, and protein synthesis
activity in the stages immediately before and after immunoglo-
bulin heavy chain gene rearrangement (Fig. 5d, Supplementary
Fig. 6d, arrows & gray box). Previously, we demonstrated that this
coordination point lead to rewiring of the B-cell signaling
network, highlighted here by S6 activation following the first
detectable expression of B cell immunoglobulin heavy chain
(IgM)45 (Fig. 5d, Supplementary Fig. 6d, right arrow). Strikingly,
while developmentally flanked by cells displaying bursts of
proliferation and translational activity, it was only following the
pro- to pre-B cell coordination point that we see a marked
increase in RNA synthesis activity for the first time coinciding
with the signaling network re-wiring event (Fig. 5d, Supplemen-
tary Fig. 6d, BRU). Collectively, SOM3B identified key coordina-
tion points of macromolecule synthesis during B-cell maturation,
highlighting a transcriptional burst associated with the re-wired
signaling state for the first time in a fleeting fraction of B cells that
can be less than 0.01% of the marrow45.
Discussion
Here, we described SOM3B, a simple method to simultaneously
capture DNA, RNA, and protein synthesis activity of individual
cells in parallel with highly multiplexed single cell analysis.
SOM3B does not require complex cell manipulation, and as
established here, can readily be applied to ex vivo primary human
samples for investigation of heterogeneous behavior in complex
tissues. We demonstrated several applications of SOM3B,
including the detailed analysis of biosynthesis activities in human
cell line cell-cycle continuums, primary human immune cells, and
across the hematopoietic hierarchy of healthy human donors.
Importantly, the sensitivity and range of measureable activity
captured with SOM3B was established by using a combination of
specific inhibitors and the investigation of cell states with pre-
viously documented activities of these processes measured with
orthogonal approaches in human cell lines. These validation
experiments encouraged us to apply SOM3B to more complex cell
populations, including primary human samples.
While single cell activity measurements reported here are the
first datasets produced using SOM3B, the presented data on
human immune cell activity can be informed and supported by
recent investigations in mouse and historical investigations in
human. In mouse, Signer and colleagues10,12 observed a regulated
protein synthesis rate across developmentally linked sub-popu-
lations, first highlighting a reduced rate of protein synthesis in
hematopoietic stem cells relative to whole bone marrow and
additional identified progenitor populations, an observation also
present within our human datasets. Single cell analysis of protein
synthesis in mouse lymphocytes also illustrated an increase in
protein synthesis activity after exposure to stimulatory
molecules7,11 or virus8. Finally, the erythroid compartment
identified within our human bone marrow datasets displayed a
progressive increase in the frequency of cells synthesizing DNA,
RNA and protein. Likewise, the mouse erythroid developmental
trajectory from early to late progenitors is characterized by a
positive association of cell-cycle remodeling, demonstrated by a
steady increase in the proportion of cells actively synthesizing
DNA in progressive erythroid developmental subsets in fetal
liver48 and bone marrow49.
Past investigations of human bone marrow cell metabolism
obtained with radioactive pre-cursor molecules corresponds with
results obtained with SOM3B and presented here. Incorporation
of radioactive precursor molecules illustrated high activity of
DNA and RNA synthesis in immature bone marrow cells relative
to mature cell types13, consistent with our results with SOM3B in
which there was no detectable DNA and very little de novo RNA
synthesis in mature lymphocyte populations. Further, analysis of
radioactive amino acid incorporation in distinct bone marrow
cells illustrated a high activity of protein synthesis in immature
cell types relative to mature immune cells, similar to the activity
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of DNA and RNA synthesis9,13. Importantly, a consistent trend of
maintained protein synthesis in the absence of strong RNA
synthesis activity in lymphocyte cell types is observed in experi-
ments with radioactive pre-cursor molecules9 and here with
SOM3B reagents. Taken together, the collective characteristics of
biosynthesis activities previously reported in a spectrum of
mouse7,8,10–12,48,49 and human9,13 immune cells support results
presented here using SOM3B.
Here we demonstrate the utility of SOM3B to create regulatory
models of sophisticated cell systems. An important consideration
when using SOM3B is the adequate optimization of reagents for
the cell type of interest, and inclusion of control conditions
including matched, un-labeled cells and/or cells pre-treated with
small molecule inhibitors of the biosynthesis processes them-
selves. This will enable identification of thresholds to set for IdU
incorporation and determination of background signal derived
from technical artifacts or non-specific binding of antibodies. We
envision its combination with prospective isolation schemes for
the timing and targeting of cell populations with unique macro-
molecule synthesis profiles, followed by orthogonal molecular
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Fig. 5 Dynamic DNA, RNA, and protein synthesis across a human hematopoietic continuum can be linked to cellular function and developmental identity.
a Plot of CD45pos immune cells from a healthy human bone marrow donor (color overlaid: IdU incorporation, color range: 0, 410 ion counts). Arrows
highlight cells with high activity of RNA or protein synthesis, arrowhead indicates high biosynthesis activity of all three biomolecules. bManually annotated
SPADE map of single cell data in a, clustered according to immune-cell phenotype and color-overlaid by the median incorporated puromycin (left), BRU
(top right) and ribosomal RNA expression (bottom right) for each cluster. c Quantification of DNA synthesis (percent IdU positive), RNA and protein
synthesis for each phenotype group in b. Values are displayed for both IdU positive and IdU negative sub-populations only when greater than 4% of the
parent population is positive for IdU. Error bars, 95 percent bootstrap confidence interval, see Supplementary Table 6 for total cell observations in each
phenotypic group. Arrows highlight plasma cells. d Wanderlust trajectory analysis of B-cell lineage (underlined in b) ordered according to developmental
pseudo-time with functional markers (top), and activity of DNA, RNA, protein synthesis, and p-S6 expression in the same B-cell developmental axis
(bottom). Arrowheads highlight developmental stages immediately before, and after, B-cell somatic recombination. Experiment was performed on two
independent donor bone marrow samples, with data from the additional donor presented in Supplementary Fig. 6. p-values symbols expressed as follows:
1.0 × 10−7 > p > 1.0 × 10−14*; 1.0 × 10−14 > p > 1.0 × 10−21**; 1.0 × 10−21 > p > 1.0 × 10−28***; p < 1.0 × 10−28****. Significance was obtained by the Friedman-
Rafsky test, evaluating BRU and puromycin incorporation in a given phenotypic population relative to HSC
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profiling and affinity-based purification methods to facilitate de
novo discovery of actively regulated molecules (e.g. BRU-seq25).
Such partnerships will not only provide a profile of molecules
contributing to activities measured with SOM3B, but also provide
an avenue to address molecular underpinnings driving cell-type
specific biosynthesis activities. Importantly, while SOM3B is
presented here in partnership with mass-cytometry to enable
direct measurement of nascent DNA3, and robust multiplexing of
molecular targets and sample conditions17,41, use of metabolic
pre-cursors and detection reagents optimized for fluorescent
detection (e.g. fluorescently labeled antibodies against BRU4,6 and
puromycin7,11, click-chemistry assisted DNA50 or RNA5 synth-
esis activity, etc.) will allow parallel assessment with less com-
prehensive, but widely used, detection systems such as fluorescent
flow cytometry. Moreover, SOM3B can conceivably be combined
with newly developed single-cell sequencing methods (i.e. CITE-
seq), which can quantify both endogenous mRNA and nucleotide
tagged antibodies51. Finally, we expect that SOM3B should be
extendible to animal models, enabling in vivo biosynthesis
activity approximations in disease models and various genetic
backgrounds, altogether highlighting multiple applications of
SOM3B in different areas of life science research.
Methods
Labeling molecules. 5-Iodo-2-deoxyuridine (Sigma I7125) was re-suspended in
DMSO (Sigma D2650) at 500 mM, 5-Bromouridine (Sigma 850187) was re-
suspended in Dulbecco’s Phosphate-Buffered Saline (DPBS, Thermo Fisher
14190250) at 100 mM, and puromycin (P212121 58-58-2) was re-suspended in
double distilled water at 1 mg/mL. Solutions were gently heated in a 50 °C water
bath to completely dissolve solute when necessary. To label nascent DNA, RNA,
and polypeptides, all three label molecules were added together and mixed thor-
oughly with media from actively dividing cells (final concentration in media: IdU;
100 μM, BRU; 2–5 mM, puromycin; 1–10 μg/mL), and then returned to the culture
dish for a labeling duration of 10–30 min. Thresholds for cells actively synthesizing
DNA were determined by inclusion of unlabeled controls from the same cell type.
Cell culture. HeLa (ATCC CCL-2) and Jurkat (ATCC CRL-2899) cells were
maintained in DMEM and RPMI (Gibco), respectively, at 37 °C 5% CO2. Human
Embryonal Kidney (HEK 293T, ATCC CRL-3216) cells used for puromycin
antibody titrations were cultured in the same manner as HeLa cells. Cell culture
media for both HeLa and Jurkat cell lines was supplemented with 10% Fetal Bovine
Serum (Sigma) and GlutaMAX supplement (Thermo Fisher). For inhibitor
experiments, Cycloheximide solution (Sigma C4859) was added directly to cell
culture media at the indicated final concentrations. Actinomycin D powder (Sigma
A1410) was dissolved in DMSO at 1 mM, and was also added directly to cell
culture media at the indicated final concentrations. After 30 min of inhibitor
treatment, a mixture of all three labeling molecules was added directly in the same
culture media containing inhibitor and returned to the incubator for 30 more
minutes before harvesting.
To harvest, HeLa cells were washed with DPBS twice, incubated with Accumax
(Thermo Fisher) for 3–5 min at 37 °C, and subsequently mechanically dissociated
into single cell suspension with a P1000 micropipette. Jurkat cells were pipetted
thoroughly with a P1000 micropipette to dissociate cell clumps.
Single cell suspensions were centrifuged at room temperature for 5 min, 250G,
and supernatant aspirated. Cell pellets were re-suspended with cisplatin for 5 min
at room temperature (Sigma, 0.5 μM final concentration in DPBS), to label non-
viable cells42. Cells were next washed with DPBS, and fixed with 1.6%
paraformaldehyde (Electron Microscopy Sciences, diluted in DPBS), for 10 min at
room temperature. Fixed cells were washed with DPBS, re-suspended in Cell-
Staining Medium (CSM: PBS with 0.5% BSA and 0.02% NaN3) and immediately
continued to staining with metal-isotope antibodies, or stored long term at −80C.
All centrifugations of fixed cells were 5 min, 550 × g at 4 °C.
Blood donors. All human blood and bone marrow samples were obtained and
experimental procedures were carried out in accordance with the guidelines of the
Stanford Institutional Review Board. The experimental procedures / protocols in
combination with the samples used in this study were approved under Stanford
IRB protocol #42195, which was reviewed by Stanford IRB panel IRB-98.
Ex vivo stimulation of primary human peripheral blood. Four heparinized tubes
of whole blood from a single healthy donor was obtained from the Stanford Blood
Center on the same day it was collected from the donor. Immediately after
receiving, whole blood was equally distributed into 10 tubes, and all were placed in
a 37 °C 5% CO2 incubator for 30 min before stimulation.
After resting whole blood for 30 min at 37 °C, brefeldin A solution (BioLegend)
was added to each stimulation tube to block membrane vesicle transport and
permit intracellular detection of induced cytokine protein expression, including the
“No stimulation/0 h” control sample. At the same time, PMA (Sigma, 50 nM) and
Ionomycin (Sigma, 1 μg/mL) was added to the 5-hour stimulation sample (t= 0 h),
with the remaining tubes receiving PMA and Ionomycin at set intervals to yield a
time-course of cell activation (stimulation duration: 0, 0.25, 0.5, 1, 2, 5 h). A pre-
mixed solution of IdU (100 μM), BRU (5 mM), and puromycin (10 μg/mL) was
added to all tubes at t= 4.5 h and mixed thoroughly. Cisplatin (1 μM) was added
for the final 5 min to stain non-viable cells. At t= 5 h, Phosflow Lyse/Fix Buffer
(BD Biosciences, Cat. #558049) was added to all six tubes to lyse red blood cells and
simultaneously fix mononuclear cells, including granulocytes and platelets, which
are removed from downstream analysis in silico (Fig. S3, Table S3). After fixation at
room temperature for 15 min, cells were washed with DPBS twice, re-suspended in
CSM and stored at −80 °C until antibody staining.
In addition to the stimulation time-course, remaining tubes of whole blood
from the same donor were treated with either (1) 1 μM cycloheximide, (2) 1 μM
actinomyocin d, or (3) DMSO for 30 min, followed by addition of a pre-mixed
solution of IdU, BRU, and puromycin for another 30 min (same concentration as
stimulation tubes). The final tube was left un-treated and did not receive any
labeling molecules to serve as an unstimulated, non SOM3B labeled control. As
with the stimulation tubes, all four tubes received Phosflow Lyse/Fix Buffer (BD
Biosciences, Cat. #558049) at the same time, were then incubated at room
temperature for 15 min, and were washed twice with DPBS and stored in CSM.
Prior to antibody staining, 5 × 106 cells from each of the 10 aforementioned sample
conditions were metal-isotope barcoded with palladium isotopes17 and
subsequently pooled into a single tube for antibody staining.
Ex vivo labeling human bone marrow. Fresh bone marrow aspirates from two
independent donors were obtained from AllCells (Alameda, CA) on the same day
of collection, and immediately after receiving was placed in 37 °C 5% CO2 incu-
bator for 30 min prior to SOM3B labeling. A mixture of all three label molecules
was added together and mixed thoroughly (final concentration; IdU—100 μM,
BRU—2 mM, puromycin—10 μg/mL), and then added to pre-warmed bone mar-
row and returned to 37 °C 5% CO2 incubator for 30 min.
Mono-nuclear cells were subsequently isolated from whole bone marrow with
Ficoll to remove granulocytes and erythrocytes, following manufacture instruction
(GE Life Sciences, 17144003), and fixed with 1.6% paraformaldehyde diluted in
DPBS for 10 min at room temperature, washed with DPBS, and stored in CSM at
−80 °C until antibody staining.
For antibody staining, 10 × 106 cells from both donors were barcoded17 and
pooled in a single tube for antibody staining.
Antibody staining and data acquisition. All metal-isotope labeled antibodies used
in this study were conjugated and validated as previously described3,41,52,53, using
the MaxPar X8 Antibody Labeling kit per manufacturer instruction (Fluidigm), or
were purchased from Fluidigm pre-conjugated. A list of staining concentrations
and manufacturer information for each antibody used is found in Supplementary
Tables 1, 2 and 4. Purified anti-BRdU (BD, Cat# 555627) was in-house conjugated
and used to detect incorporated BRU, as was purified anti-Puromycin (Milli-
poreSigma, Cat# MABE343). Each conjugated antibody was quality checked and
titrated to optimal staining concentration using a combination of primary human
cells and/or cancer cell lines. Optimal concentrations of antibodies used in this
study were selected based on visual inspection of performed titration on positive
and negative cell types, with optimal concentrations demonstrating high signal-to-
noise ratio.
Cell staining was performed as previously described for mass-cytometry
analysis3,45,52. Briefly, fixed cells stored in CSM from a single sample, or barcoded17
and subsequently pooled cells, were washed with CSM once then centrifuged to
pellet cells. For cells stained in the presence of RNase inhibitors, inhibitors were
added to every buffer used at their indicated concentration beginning at this point.
A mixture of all isotope-labeled antibodies against extracellular antigens was
filtered (Ultrafree centrifugal filter—0.1 μm) to remove any precipitate. The filtered
antibody cocktail was added to cells suspended in a total volume of 100 μL and
incubated at room temperature for 30 min. Surface-stained cells were then washed
once with CSM, and permeabilized with ice cold methanol (Sigma), on ice for
10 min. Membrane permeabilized cells were washed twice with CSM, and all
isotope-labeled antibodies against intracellular antigens were pre-mixed and
filtered before staining in the same fashion as surface antibodies. After intracellular
antibody staining, cells were washed once with CSM and then re-suspended in
DNA intercalator solution (1.6% PFA diluted in PBS, 1:5000 DNA intercalator
from Fluidigm) until ready for data acquisition on a CyTOF 2. This duration was
for at least 20 min at room temperature when samples were analyzed by mass-
cytometry on the same day, or overnight at 4 °C for acquisition on the day after
sample staining.
To prepare cells for acquisition on a CyTOF 2, cells in DNA intercalator were
washed once with CSM, and then twice in double distilled water (ddH2O). EQ Four
element calibration beads (Fluidigm) were diluted in ddH2O 1:10, and were
subsequently used to re-suspend stained cells (~106 cells/mL) to be injected into
the CyTOF 2. Single cell events were recorded at an event rate of ~500 cells/second.
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Mass-cytometry data analysis. After data acquisition, FCS files with single cell
data were normalized, de-barcoded, and transformed using the inverse hyperbolic
sine (ArcSinh) function with a cofactor of 552. Non-viable (cisplatin positive) and
actively apoptotic (cleaved-PARP and/or cleaved-Caspase3 positive) cells were
removed for all subsequent data analysis. Histograms, biaxial plots, heat plots, and
SPADE clustering were created and performed, respectively, using cytobank.org.
All data presented for experiments performed on transformed human cell lines
contain 90,000–100,000 single cell events per experimental condition unless
otherwise noted. All data presented for primary peripheral blood contains 95,000 to
170,000 viable, non-apoptotic single cell events per experimental sample unless
otherwise noted. Gating thresholds for IdU incorporation were set based off of
unlabeled-control cells. Importantly, these thresholds should be determined by
performing a control experiment with un-labeled cells for SOM3B experiments
performed on new cell types and/or systems, as some cell lines display variable
background incorporation of IdU.
Bootstrap median and confidence intervals, and Friedman-Rafsky (FR)
statistics, generated for Jurkat cell data presented in Supplementary Fig. 1e, f were
obtained using the same parameters as performed with bone marrow data (further
explanation below). For each class of incorporated molecule (i.e. IdU, BRU, and
puromycin), an FR probability statistic was generated by comparing single-cell
distribution for a given molecule in combination with p4EBP1(Thr37/46)
expression, between the indicated experimental condition to the ‘IdU+ BRU+
Puro’ sample (IdU incorporation was evaluated using only IdUpositive events).
This generates a probability value indicating similarity of the incorporated
molecule and 4EBP1 phosphorylation expression distributions in Jurkat cells
labeled with all three molecules compared with double- or single-label controls. See
section below on bone marrow data analysis for further detail and relevant
references.
For peripheral blood experiments, mononuclear cells were isolated in silico
(Supplementary Fig. 3), and subsequently clustered by cell phenotype with SPADE
(down-sampled events target: 15 percent, target number of nodes: 150). Meta-
clusters were annotated using established phenotypic markers (Supplementary
Table 3), and marker expression (or molecule incorporation) in each population of
interest was determined by calculating the difference in the ArcSinh transformed
median values for a given time point, relative to the corresponding population in
the no-stimulation control sample.
For analyzed bone marrow cells, CD45 positive cell events (Supplementary
Fig. 5) were clustered by cell phenotype with SPADE (down-sampled events target:
15 percent, target number of nodes: 175). Meta-clusters were annotated using
established phenotypic markers (Supplementary Table 5), and cell events within
each phenotypic cluster were exported from cytobank as individual FCS files and
subsequently analyzed in RStudio (Version 1.0.153). The frequency of cells with
greater than 10 counts of incorporated IdU was used to quantify DNA synthesis
activity for each immune-cell phenotype cluster, determined by visual comparison
between unlabeled and IdU labeled samples. Bootstrap statistics were generated
using boot54,55 and flowCore56 libraries. Ordinary Nonparametric Bootstrap was
used and replicated 1000 times (R= 1000) for each immune-cell phenotype cluster
to obtain the bootstrapped median values and 95% confidence intervals for each
analyzed phenotypic cluster, with sampling from the raw single cell data of each
assigned phenotypic cluster. Supplementary Table 6 displays the total number of
cell observations in each phenotypic cluster presented in Fig. 5 and Supplementary
Fig. 6. Graph figures were created in Prism (graphpad).
Statistical testing to evaluate the equivalence of BRU and Puromycin
incorporation between the Hematopoietic Stem Cell (HSC) population relative to
each additional bone marrow populations was evaluated using FlowMap-FR, of the
flowMap library57, implemented in R. FlowMap-FR46 is an analytical and statistical
tool used to compare multivariate single-cell expression data between cell
populations. In brief, a pooled sub-dataset is made containing an equal number of
single cell events from the two populations under comparison. Next a minimum
spanning tree (MST) is generated using the Euclidean distance between all cell
pairs in the pooled sub-dataset with respect to BRU and puromycin incorporation.
The Friedman-Rafsky47 statistic is derived from the extent of single-cell data
mixing in the resultant MST between both populations, by evaluating the number
of edges in the MST connecting a pair of cells that were not derived from the same
cell population. Creation of the sub-dataset and MST generation is iterated in order
to obtain a probability of population equivalence, with probabilities closer to 1
indicating that populations are likely drawn from the same distribution and small
values (i.e. p < 1.0E-7) indicating the populations are likely not derived from the
same distribution (i.e. population). For our analysis, sampling parameters S= 200
(total number of cells in the sub-dataset used generate the MST) and N= 100 (total
number of iterations) were used in calculating the p-values presented for each
donor in Supplementary Table 646. Increasing parameters to consider a larger sub-
dataset (S= 400), or more iterations (N= 500), lead to a general and consistent
decrease in p-value scores across all populations, except for control HSC vs. HSC,
as expected46.
Wanderlust45 was used to organize single cell events along the B-cell
developmental trajectory using previously characterized phenotypic markers,
implemented through the matlab GUI, CYT (Dana Pe’er Lab). Cells belonging to
the B-cell developmental trajectory were concatenated into a single FCS file before
importing into CYT. Cell parameters used to construct the linear trajectory are
found in Supplementary Table 4.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Single cell mass-cytometry datasets generated and presented for primary human
peripheral blood (FR-FCM-ZYR5) and bone marrow (FR-FCM-ZYQV) experiments are
available in flowrepository.org.
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